FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional ...

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, an ...